PARIS, France, November 8 /PRNewswire-FirstCall/ -- ExonHit Therapeutics S.A. (Alternext: ALEHT), a drug and diagnostic discovery company, announced today the appointment of Christophe Jean to its Supervisory Board.
Christophe Jean is currently Executive Vice President of Ipsen, in charge of the world wide operations and of strategic planning. He has occupied several operational jobs from 1982 to 2000 at Ciba Geigy AG then Novartis Pharma AG before joining Pierre Fabre Medicament in 2000 as President.
Christophe Jean stated: “I am enthused to join the Supervisory Board at a point in time when the company has made the decision to accelerate its development both in the diagnostic and the therapeutic domains. I will work with the Management to support the strategic planning.”
M. Christophe Jean is replacing M. Jean-Luc Belingard, President of Ipsen, who has been a member of the Supervisory Board of ExonHit for six years.
The Supervisory Board is chaired by Laurent Condomine, Vice-President Business Development at the AstraZeneca group and the Vice-Chairman is Edmund M Olivier de Vezin from Oxford BioScience Partners. The other members of the Supervisory Board are Gilles Brisson, Patrick Langlois and Michel Picot.
“It is a great pleasure to welcome Christophe to our Supervisory Board. His extensive international experience in the pharmaceutical industry will be of great value to ExonHit as we seek to bring innovation to the industry in the diagnostic business as a supporting tool for therapeutic decisions.” declares Bruno Tocque, President of the Management Board. “We are very grateful to Jean-Luc Belingard for his continued valuable support and advice over the years and for his pioneering and global vision of innovation in the Life Science sector”.
About ExonHit Therapeutics
ExonHit Therapeutics is the world’s leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases.
ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays, “SpliceArrays,” that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMérieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers.
In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative diseases and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit.
Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The Company is listed on Alternext of Euronext Paris since November 17, 2005.
Contacts ExonHit Therapeutics Bruno Tocqué, C.E.O. Philippe Rousseau, C.F.O. Tel:+33-1-58-05-47-00 philippe.rousseau@exonhit.com
This press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.
ExonHit Therapeutics SA
CONTACT: Contacts: ExonHit Therapeutics, Bruno Tocqué, C.E.O., PhilippeRousseau, C.F.O., Tel: +33-1-58-05-47-00, philippe.rousseau@exonhit.com
<
